Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Peddock Capital Advisors LLC

Peddock Capital Advisors LLC reduced its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 26.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,706 shares of the biopharmaceutical company’s stock after selling 2,070 shares during the period. Peddock Capital Advisors LLC’s holdings in Bristol-Myers Squibb were worth $293,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. FORVIS Wealth Advisors LLC grew its stake in shares of Bristol-Myers Squibb by 9.5% during the third quarter. FORVIS Wealth Advisors LLC now owns 28,257 shares of the biopharmaceutical company’s stock worth $1,640,000 after purchasing an additional 2,446 shares in the last quarter. Waldron Private Wealth LLC boosted its position in shares of Bristol-Myers Squibb by 20.5% during the 3rd quarter. Waldron Private Wealth LLC now owns 17,846 shares of the biopharmaceutical company’s stock worth $1,035,000 after acquiring an additional 3,032 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Bristol-Myers Squibb by 3.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 463,064 shares of the biopharmaceutical company’s stock valued at $26,876,000 after acquiring an additional 13,562 shares during the last quarter. NBT Bank N A NY raised its position in shares of Bristol-Myers Squibb by 17.8% during the 3rd quarter. NBT Bank N A NY now owns 99,103 shares of the biopharmaceutical company’s stock worth $5,752,000 after acquiring an additional 14,940 shares in the last quarter. Finally, River Street Advisors LLC boosted its holdings in Bristol-Myers Squibb by 4.7% in the third quarter. River Street Advisors LLC now owns 11,696 shares of the biopharmaceutical company’s stock valued at $679,000 after purchasing an additional 526 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 0.3 %

NYSE:BMY traded up $0.14 on Tuesday, reaching $44.04. The stock had a trading volume of 10,924,172 shares, compared to its average volume of 15,784,603. Bristol-Myers Squibb has a 12-month low of $43.33 and a 12-month high of $69.10. The company has a market cap of $89.27 billion, a price-to-earnings ratio of -14.21, a P/E/G ratio of 14.82 and a beta of 0.45. The firm’s fifty day moving average is $50.11 and its two-hundred day moving average is $50.48. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.05 earnings per share. Equities analysts expect that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were paid a $0.60 dividend. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 5.45%. Bristol-Myers Squibb’s payout ratio is currently -77.42%.

Wall Street Analyst Weigh In

BMY has been the subject of several recent analyst reports. BMO Capital Markets reduced their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, Barclays lowered their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.